Tharimmune Change in Accounts Receivable 2021-2025 | THAR

Tharimmune change in accounts receivable from 2021 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Tharimmune Change in Accounts Receivable 2021-2025 | THAR

Tharimmune change in accounts receivable from 2021 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$246.7B
Amgen (AMGN)$159.1B
Gilead Sciences (GILD)$146.4B
Vertex Pharmaceuticals (VRTX)$100.2B
Bristol Myers Squibb (BMY)$98.4B
GSK (GSK)$80.7B
CSL (CSLLY)$70.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Alnylam Pharmaceuticals (ALNY)$60.1B
Argenex SE (ARGX)$40.2B
Insmed (INSM)$26.9B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.7B
Illumina (ILMN)$15.6B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15.3B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.1B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.6B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.2B
Roivant Sciences (ROIV)$8B